top of page
Our company
Harnessing evolution
for genetic reprogramming
of immune cells in the body
TRANSFORMING IMMUNE CELLS.
EXPANDING POSSIBILITIES.
We are providing solutions to two main hurdles
in cell therapy for liquid and solid tumors
I
In vivo CAR-T cell therapy serves as
next-generation CAR-T therapy
II
Multiple barriers exist in solid tumors
The tumor microenvironment limits effective CAR-T cell delivery, infiltration, and persistence
III
Engineering every component for superior in vivo CAR-T cells
We systematically screen and optimize vector, scFv, CAR, and genomic designs to identify the best combination for each indication.
![Subtract [Vectorized].png](https://static.wixstatic.com/media/c1c5ab_49d562d9607348d485ef6c626d880226~mv2.png/v1/crop/x_1,y_0,w_711,h_641/fill/w_551,h_497,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/Subtract%20%5BVectorized%5D.png)
bottom of page